Andrew Ratz - 15 Mar 2026 Form 3 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Technical Operations Off
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
15 Mar 2026
Net transactions value
$0
Form type
3
Filing time
17 Mar 2026, 17:56:51 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ratz Andrew Chief Technical Operations Off 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 17 Mar 2026 0002117222

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NBIX Common Stock 1,018 15 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NBIX Restricted Stock Unit 15 Mar 2026 Common Stock 3,997 Direct F1, F2
holding NBIX Restricted Stock Unit 15 Mar 2026 Common Stock 5,640 Direct F2, F3
holding NBIX Incentive Stock Option 15 Mar 2026 Common Stock 2,664 $150.10 Direct F4
holding NBIX Non-Qualified Stock Option 15 Mar 2026 Common Stock 17,724 $150.10 Direct F4
holding NBIX Incentive Stock Option 15 Mar 2026 Common Stock 805 $124.12 Direct F5
holding NBIX Non-Qualified Stock Option 15 Mar 2026 Common Stock 31,348 $124.12 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units (RSUs) remaining outstanding as of March 15, 2026. The RSU vested and settled as to 1/4 of the total units on February 3, 2026. The remaining RSUs vest annually at 1/4 of the total units subject to the award vesting on each of February 3, 2027, February 3, 2028, and February 3, 2029.
F2 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
F4 Represents option of which 1/4th of the shares underlying the option became vested and exercisable on February 3, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F5 Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.